Cancer-associated immune-mediated syndromes: Pathogenic values and clinical implementation

Biomedicine and Pharmacotherapy

Volumn 61, Issue 6, 2007, Pages 323-337

  Suchkov, S V ^a,b   Petrunin, D D ^c   Kostalevskaya, A V ^a   Kachkov, I A ^b   Elbeik, T ^d,e   Matsuura, E ^f   Paltsev, M A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Professional Habitat Design   (United States)

^f OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adaptive immunity; Anti tumor immunity; Apoptosis; Basal cell carcinoma; Cancer associated immune mediated syndrome; Cancer associated secondary immunodeficiency (CASID); Cancer associated secondary immunodeficiency with clinical autoimmunity syndrome (CASICAS); Cytotoxicity; Dendritic cells; Glioblastoma multiforme; Innate immunity

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER ASSOCIATED SECONDARY IMMUNODEFICIENCY; CANCER ASSOCIATED SECONDARY IMMUNODEFICIENCY WITH CLINICAL AUTOIMMUNITY SYNDROME; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNITY; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; NEOPLASMS; PHAGOCYTES; T-LYMPHOCYTES;

EID: 34547544881     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.06.007     Document Type: Article

References (85)

1. Mantovani A., Schioppa T., Porta C., Allavena P., and Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25 3 (2006) 315-322
2. Proia D.A., and Kuperwasser C. Stroma: tumor agonist or antagonist. Cell Cycle 4 8 (2005) 1022-1025
3. Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med 6 6 (2006) 685-693
4. Bruner J.M. Neuropathology of malignant gliomas. Semin Oncol 21 (1994) 126-138
5. Burton E.C., and Prados M.D. Malignant gliomas. Curr Treat Options Oncol 1 5 (2000) 459-468
6. Palanichamy K., Erkkinen M., and Chakravarti A. Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 7 6 (2006) 490-504
7. Seker A., and Ozek M.M. Congenital glioblastoma multiforme Case report and review of the literature. J Neurosurg 105 6 (2006) 473-479
8. Bath-Hextall F., Bong J., Perkins W., and Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 329 7468 (2004) 705-714
9. Brooke R.C. Basal cell carcinoma. Clin Med 5 6 (2005) 551-554
10. Crowson A.N. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 19 2 (2006) 127-147
11. Lear W., Dahlke E., and Murray C.A. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg 11 1 (2007) 19-30
12. Rubin A.I., Chen E.H., and Ratner D. Basal-cell carcinoma. N Engl J Med 353 21 (2005) 2262-2269
13. Smeets N. Little evidence available on treatments for basal cell carcinoma of the skin. Cancer Treat Rev 31 2 (2005) 143-146
14. Akasaki Y., Black K.L., and Yu J.S. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches. Front Biosci 10 (2005) 2908-2921
15. Dhodapkar K.M., Banerjee D., and Steinman R.M. Harnessing the immune system against human glioma. Ann NY Acad Sci 1062 (2005) 13-21
16. Friese M.A., Steinle A., and Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie 27 5 (2004) 487-490
17. Grimwood R.E. Immune response to basal cell and squamous cell carcinomas. Immunol Ser 46 (1989) 789-798
18. Hussain S.F., and Heimberger A.B. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther 5 5 (2005) 777-790
19. Myskowski P.L., and Safai B. The immunology of basal cell carcinoma. Int J Dermatol 27 9 (1988) 601-607
20. Okada H., and Pollack I.F. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4 10 (2004) 1609-1620
21. Parajuli P., and Sloan A.E. Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22 3 (2004) 405-416
22. Prins R.M., and Liau L.M. Cellular immunity and immunotherapy of brain tumors. Front Biosci 1 9 (2004) 3124-3136
23. Schluesener H.J., Meyermann R., and Deininger M. Immune responses in glioblastoma: an avenue to effective cancer therapy or a mere epiphenomenon?. Curr Top Microbiol Immunol 265 (2002) 259-267
24. Walker P.R., and Dietrich P.Y. Immune escape of gliomas. Prog Brain Res 132 (2001) 685-698
25. Yang L., Ng K.Y., and Lillehei K.O. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10 2 (2003) 138-147
26. Wiestler O.D., Schiffer D., Coons S.W., Prayson R.A., and Rosenblum M.K. Ependymal tumors. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics of tumors of the nervous system (2000), IARC Press, Lyon 71-81
27. Korshunov A.G., and Sycheva R.V. Analysis of the interrelationships between proliferative activity of benign and anaplastic astrocytomas of the brain and the features of their pathomorphology. Voprosy Neurokhirurgii 1 (1997) 30-34 (in Russian)
28. Korshunov A.G., Sycheva R.V., and Golanov A.V. Immunohistochemical analysis of apoptosis in glioblastomas of the brain. Arkhive Patologii 60 (1998) 23-27 (in Russian)
29. Ackerman A.B., Jacobson M., and Vitale P. Clues to diagnosis in dermatopathology (1991), ASCP Press, Chicago 245-248
30. Sexton M., Jones D.B., and Maloney M.E. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23 6 Pt 1 (1990) 1118-1126
31. Boyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 4 4 (1974) 269-274
32. Tamura H., Ogata K., Dong H., and Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78 4 (2003) 321-328
33. Mancini G., Carbonara A.O., and Heremans J.F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2 3 (1965) 235-254
34. Herreman G., Godeau P., Cabane J., Acar J.F., Digeon M., and Bach J.F. Circulating immuns complexes and infections endocarditis. Ann Med Interne (Paris) 129 6-7 (1978) 387-397
35. Hartmann H., Lubbers B., Casaretto M., Bautsch W., Klos A., and Kohl J. Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J Immunol Methods 166 1 (1993) 35-44
36. Soares N.M., Santiago M.B., and Pontes deCarvalho L.C. An improved anti-C3/IgG ELISA for quantification of soluble immune complexes. J Immunol Methods 249 1-2 (2001) 199-205
37. Hampton M.B., and Winterbourn C.C. Methods for quantifying phagocytosis and bacterial killing by human neutrophils. J Immunol Methods 232 1-2 (1999) 15-22
38. Dorofeev A.E., Snarskaya E.S., SYu A., Kostalevskaya A.V., Petrunin D.D., Pronina O.A., et al. Blood cell subsets spectrum in patients with slin basaliomas: pathogenic and clinical values. Molekulyarnaya meditsina 4 (2006) 38-45 (in Russian)
39. Bohbot A., Feugeas O., Cuillerot J.M., Grosse A., Rusciani I., Faradji A., and Oberling F. Peripheral blood CD34+ cells: method of purification and ex vivo expansion. Nouv Rev Fr Hematol 37 6 (1995) 359-365
40. Amel-Kashipaz M.R., Huggins M.L., Lanyon P., Robins A., Todd I., and Powell R.J. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus. J Autoimmun 17 2 (2001) 155-161
41. Dorofeev A.V., Snarskaya E.S., Molochkov V.A., Chelyukanova M.V., Alentyeva S., Pronina O.A., et al. Pathogenic and clinical values of the features of the innate and adaptive links of the immunity in patients with basal cell carcinoma. Rossiiskii jurnal kojnyh i venericheskih boleznei 3 (2005) 8-15 (in Russian)
42. Hempel G., Galle P.R., and Lohr H.F. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C. J Med Virol 64 3 (2001) 340-349
43. Chumakov V.A., Pronina O.A., Kachkov I.A., Korshunov A.G., Pinegin B.V., Ananyeva II, et al. Features of the blood cell subsets spectrum in patients with glioblastomas: clinical implementations. Meditsinskaya Immunologiya 8 1 (2006) 37-50 (in Russian)
44. Kachkov I.A., Biktimirov R.G., Zaharov A.V., Chumakov V.A., and Suchkov S.V. Brain gliomas: classification and modern aspects of the immunopathogenesis and immune and gene diagnostic. Vestnik RAMN 6 (2005) 36-41 (in Russian)
45. Kuzyakina L.V., Snarskaya E.S., Dorofeev A.E., Ananyeva II, Pinegin B.V., SYu A., et al. Features of the blood cytokine spectrum in patients with glioblastomas: pathogenic and clinical implementations. Tsytokines I vospalenie 5 3 (2006) 21-26 (in Russian)
46. Snarskaya E.S., Molochkov V.A., and Suchkov S.V. Modern protocols of the treatment and rehabilitation modalities in basaliomas: pathogenic background and clinical efficacy. Vestnik RAMN 6 (2005) 41-45 (in Russian)
47. Fujimoto Y., and Tedder T.F. CD83: a regulatory molecule of the immune system with great potential for therapeutic application. J Med Dent Sci 53 2 (2006) 85-91
48. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
49. Barnetson R.S., and Halliday G.M. Regression in skin tumours: a common phenomenon. Australas J Dermatol 38 1 (1997) S63-S65
50. Ceballos P.I., and Barnhill R.L. Spontaneous regression of cutaneous tumors. Adv Dermatol 8 (1993) 229-261
51. Erb P., Ji J., Wernli M., Kump E., Glaser A., and Buchner S.A. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett 100 1 (2005) 68-72
52. Sibbitt Jr. W.L. Oncogenes, growth factors, and autoimmune diseases (review). Anticancer Res 11 1 (1991) 97-113
53. Deininger M.H., Meyermann R., and Schluesener H.J. Expression and release of CD14 in astrocytic brain tumors. Neuropathol (Berlin) 106 (2003) 271-277
54. Klein E., and Mantovani A. Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 5 5 (1993) 714-718
55. Poggi A., and Zocchi M.R. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) 54 5 (2006) 323-333
56. Deng J.S., Falo Jr. L.D., Kim B., and Abell E. Cytotoxic T cells in basal cell carcinomas of skin. Am J Dermatopathol 20 2 (1998) 143-146
57. + cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 77 (2003) 175-179
58. Perrin G., Schnuriger V., Quiquerez A.L., Saas P., Pannetier C., de Tribolet N., et al. Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11 (1999) 1337-1350
59. Montelli T.C., Peracoli M.T., Gabarra R.C., Soares A.M., and Kurokawa C.S. Familial cancer: depressed NK-cell cytotoxicity in healthy and cancer affected members. Arq Neuropsiquiatr 59 (2001) 6-10
60. Berczi I., Bertok L., and Chow D.A. Natural immunity and neuroimmune host defense. Ann NY Acad. Sci 917 (2000) 248-257
61. Aoki M., Pawankar R., Niimi Y., and Kawana S. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol 130 3 (2003) 216-223
62. Hermiston M.L., Xu Z., and Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21 (2003) 107-137
63. Irie-Sasaki J., Sasaki T., and Penninger J.M. CD45 regulated signaling pathways. Curr Top Med Chem 3 7 (2003) 783-796
64. Nguyen Q.H., Moy R.L., Roth M.D., Yamamoto R., Tomono S., and Dubinett S.M. Expression of CD45 isoforms in fresh and IL-2-cultured tumor-infiltrating lymphocytes from basal cell carcinoma. Cell Immunol 146 2 (1993) 421-430
65. Wintterle S., Schreiner B., Mitsdoerffer M., Schneider D., Chen L., Meyermann R., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 (2003) 7462-7467
66. Kaur P., Mulvaney M., and Carlson J.A. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 28 4 (2006) 293-307
67. Schreiner B., Wischhusen J., Mitsdoerffer M., Schneider D., Bornemann A., Melms A., et al. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 44 (2003) 296-301
68. Harabin-Slowinska M., Slowinski J., Konecki J., and Mrowka R. Expression of adhesion molecule CD44 in metastatic brain tumors. Folia Neuropathol 36 (1998) 179-184
69. Cichy J., and Pure E. The liberation of CD44. J Cell Biol 161 (2003) 839-843
70. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 161 (2003) 195-200
71. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4 (2003) 33-45
72. Yasuda M., Nakano K., Yasumoto K., and Tanaka Y. CD44: functional relevance to inflammation and malignancy. Histol Histopathol 17 (2002) 945-950
73. Levy S., Todd S.C., and Maecker H.T. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16 (1998) 89-109
74. Rubinstein E., Naour F.L., and Lagaudriere-Gesbert C. CD9, CD63, CD81 and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 26 (1996) 2657-2665
75. Maecker H.T., Todd S.C., and Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 11 6 (1997) 428-442
76. Billings S.D., Folpe A.L., and Weiss S.W. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 27 1 (2003) 48-57
77. Ordonez N.G. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 33 10 (2002) 953-967
78. Ottaiano A., Pisano C., De Chiara A., Ascierto P.A., Botti G., and Barletta E. et al CD40 activation as potential tool in malignant neoplasms. Tumori 88 5 (2002) 361-366
79. Shidham V.B., Chivukula M., Gupta D., Rao R.N., and Komorowski R. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med 126 10 (2002) 1189-1192
80. Ylagan L.R., Scholes J., and Demopoulos R. Cd44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 124 2 (2000) 212-215
81. Chin C.W., Foss A.J., Stevens A., and Lowe J. Differences in the vascular patterns of basal and squamous cell skin carcinomas explain their differences in clinical behaviour. Pathology 200 3 (2003) 308-313
82. Bodmer S., Strommer K., Frei K., Siepl C., de Tribolet N., Heid I., et al. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β. J Immunol 143 (1989) 3222-3229
83. Huettner C., Paulus W., and Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146 (1995) 317-322
84. Wischhusen J., Jung G., Radovanovic I., Beier C., Steinbach J.P., Rimner A., et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62 (2002) 2592-2599
85. So T., Lee S.W., and Croft M. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 83 1 (2006) 1-11